Literature DB >> 17178818

The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases.

N M Warren1, M A Piggott, A J Lees, D J Burn.   

Abstract

BACKGROUND: Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disorder involving motor and cognitive dysfunction. Currently, there is no effective treatment either for symptomatic relief or disease modification. This relates, in part, to a lack of knowledge of the underlying neurochemical abnormalities, including cholinergic receptor status in the basal ganglia. AIM: To measure muscarinic M2 and M4 receptors in the basal ganglia in PSP.
METHODS: The muscarinic M2 (presynaptic) and M4 (postsynaptic) receptors in the striatum, pallidum and adjacent insular cortex were autoradiographically measured in pathologically confirmed cases of PSP (n = 18), and compared with cases of Lewy body dementias (LBDs; n = 45), Alzheimer's disease (AD; n = 39) and controls (n = 50).
RESULTS: In cases of PSP, there was a reduction in M2 and M4 receptors in the posterior caudate and putamen compared to controls, but no significant changes in the pallidum. Cases with AD showed lower M2 receptors in the posterior striatum. Groups with LBD and AD showed higher M2 binding in the insular cortex compared with controls.
CONCLUSIONS: The results suggest loss of posterior striatal cholinergic interneurones in PSP, and reduction in medium spiny projection neurones bearing M4 receptors. These results should be taken in the context of more widespread pathology in PSP, but may have implications for future trials of cholinergic treatments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178818      PMCID: PMC2077948          DOI: 10.1136/jnnp.2006.099937

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  33 in total

1.  Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease.

Authors:  Margaret A Piggott; Jonathan Owens; John O'Brien; Sean Colloby; John Fenwick; David Wyper; Evelyn Jaros; Mary Johnson; Robert H Perry; Elaine K Perry
Journal:  J Chem Neuroanat       Date:  2003-03       Impact factor: 3.052

2.  Treatment of Alzheimer's disease: current status and new perspectives.

Authors:  Elio Scarpini; Philip Scheltens; Howard Feldman
Journal:  Lancet Neurol       Date:  2003-09       Impact factor: 44.182

3.  Dopaminergic and cholinergic lesions in progressive supranuclear palsy.

Authors:  M Ruberg; F Javoy-Agid; E Hirsch; B Scatton; R LHeureux; J J Hauw; C Duyckaerts; F Gray; A Morel-Maroger; A Rascol
Journal:  Ann Neurol       Date:  1985-11       Impact factor: 10.422

4.  Bilateral lesions of the insular cortex or of the prefrontal cortex block the association between taste and odor in the rat.

Authors:  Nobuyuki Sakai; Sumio Imada
Journal:  Neurobiol Learn Mem       Date:  2003-07       Impact factor: 2.877

5.  Strokes restricted to the insular cortex.

Authors:  C Cereda; J Ghika; P Maeder; J Bogousslavsky
Journal:  Neurology       Date:  2002-12-24       Impact factor: 9.910

6.  Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep.

Authors:  N L Foster; M S Aldrich; L Bluemlein; R F White; S Berent
Journal:  Neurology       Date:  1989-02       Impact factor: 9.910

7.  The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

Authors:  E R Maher; A J Lees
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

Review 8.  Dementia with Lewy bodies.

Authors:  Ian McKeith; Jacobo Mintzer; Dag Aarsland; David Burn; Helen Chiu; Jiska Cohen-Mansfield; Dennis Dickson; Bruno Dubois; John E Duda; Howard Feldman; Serge Gauthier; Glenda Halliday; Brian Lawlor; Carol Lippa; Oscar L Lopez; João Carlos Machado; John O'Brien; Jeremy Playfer; Wayne Reid
Journal:  Lancet Neurol       Date:  2004-01       Impact factor: 44.182

9.  Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study.

Authors:  U Nath; Y Ben-Shlomo; R G Thomson; A J Lees; D J Burn
Journal:  Neurology       Date:  2003-03-25       Impact factor: 9.910

10.  Chemical stimulation of the thalamic reticular nucleus inhibits the neuronal activity of the posterior insular cortex in rats.

Authors:  Takamitsu Hanamori
Journal:  Chem Senses       Date:  2003-10       Impact factor: 3.160

View more
  3 in total

1.  Multireceptor fingerprints in progressive supranuclear palsy.

Authors:  Wang Zheng Chiu; Laura Donker Kaat; Agnita J W Boon; Wouter Kamphorst; Axel Schleicher; Karl Zilles; John C van Swieten; Nicola Palomero-Gallagher
Journal:  Alzheimers Res Ther       Date:  2017-04-17       Impact factor: 6.982

2.  Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson's Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy.

Authors:  Sophia Rogozinski; Martin Klietz; Gesine Respondek; Wolfgang H Oertel; Michel J Grothe; Joana B Pereira; Günter U Höglinger
Journal:  Front Aging Neurosci       Date:  2022-04-01       Impact factor: 5.702

Review 3.  Neurotransmitter deficits from frontotemporal lobar degeneration.

Authors:  Alexander G Murley; James B Rowe
Journal:  Brain       Date:  2018-05-01       Impact factor: 13.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.